NASDAQ:ENTA Enanta Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $52.10 +2.47 (+4.98%) (As of 07/5/2022 01:57 PM ET) Add Compare Share Today's Range$48.75▼$52.6150-Day Range$38.13▼$67.0452-Week Range$37.59▼$102.00Volume10,596 shsAverage Volume298,971 shsMarket Capitalization$1.08 billionP/E RatioN/ADividend YieldN/APrice Target$73.43 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Enanta Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside40.7% Upside$73.43 Price TargetShort InterestBearish10.74% of Float Sold ShortDividend StrengthN/ASustainability-1.44Upright™ Environmental ScoreNews Sentiment0.76Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.56) to ($3.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.60 out of 5 starsMedical Sector49th out of 1,428 stocksPharmaceutical Preparations Industry13th out of 680 stocks 4.4 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $73.43, Enanta Pharmaceuticals has a forecasted upside of 40.7% from its current price of $52.18.Amount of Analyst CoverageEnanta Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.74% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently increased by 6.08%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEnanta Pharmaceuticals has received a 71.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Hepatitis medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Enanta Pharmaceuticals is -1.44. Previous Next 2.6 News and Social Media Coverage News SentimentEnanta Pharmaceuticals has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest3 people have searched for ENTA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.42% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.87% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to grow in the coming year, from ($5.56) to ($3.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -9.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -9.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Enanta Pharmaceuticals (NASDAQ:ENTA) StockEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.Read More ENTA Stock News HeadlinesJuly 2, 2022 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Price Target Raised to $67.00 at Royal Bank of CanadaJuly 1, 2022 | markets.businessinsider.comAnalyst Ratings for Enanta PharmaceuticalsJuly 1, 2022 | finance.yahoo.comEnanta Pharmaceuticals Bounces Off a Key Support Level Once AgainJuly 1, 2022 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Trading 4.1% Higher June 27, 2022 | finance.yahoo.comIs Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt Sensibly?June 24, 2022 | finance.yahoo.comEnanta Pharmaceuticals (ENTA) Stock Jumps 10.1%: Will It Continue to Soar?June 24, 2022 | americanbankingnews.comJMP Securities Reiterates "Buy" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)June 23, 2022 | finance.yahoo.comCases climb in Southeast Asia and Europe in latest week as BA.4 and BA.5 subvariants take holdJune 23, 2022 | finance.yahoo.comEnanta Pharmaceuticals, which is developing its own COVID-19 antiviral, says Pfizer infringed on a patent with PaxlovidJune 22, 2022 | bizjournals.comEnanta Pharmaceuticals sues Pfizer for patent infringement involving PaxlovidJune 22, 2022 | finance.yahoo.comA small biotech says Pfizer infringed on its patent with PaxlovidJune 22, 2022 | finance.yahoo.comEnanta Pharmaceuticals Sues Pfizer Over Blockbuster Covid Pill PaxlovidJune 22, 2022 | seekingalpha.comEnanta files patent infringement lawsuit against Pfizer over PaxlovidJune 21, 2022 | finance.yahoo.comEnanta Pharmaceuticals Files Patent Infringement Suit Against PfizerJune 18, 2022 | americanbankingnews.comAnalysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $74.14June 16, 2022 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Rating Increased to Hold at StockNews.comJune 8, 2022 | finance.yahoo.comEnanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022June 1, 2022 | markets.businessinsider.comExpert Ratings for Enanta PharmaceuticalsMay 20, 2022 | benzinga.comEnanta Pharmaceuticals (NASDAQ:ENTA), Analyst Ratings, Price Targets, PredictionsMay 19, 2022 | finance.yahoo.comEnanta's stock is down after its experimental RSV treatment failed in a mid-stage clinical trialMay 18, 2022 | investing.comAfter-Hours Stock Movers 05/18: Cisco Plunges on Weak Results and Outlook; Synopsys Jumps on Results (more...)May 18, 2022 | markets.businessinsider.comEnanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary EndpointMay 18, 2022 | seekingalpha.comEnanta Pharma stock falls after phase 2b study evaluating EDP-938 did not meet main goalMay 18, 2022 | finance.yahoo.comEnanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)May 12, 2022 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Enanta PharmaceuticalsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTA CUSIPN/A CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees155Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today7/05/2022Next Earnings (Estimated)8/04/2022Fiscal Year End9/30/2022Price Target and Rating Average Stock Price Forecast$73.43 High Stock Price Forecast$103.00 Low Stock Price Forecast$44.00 Forecasted Upside/Downside+40.9%Consensus RatingModerate Buy Rating Score (0-4)2.71428571428571 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($5.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79,000,000.00 Net Margins-122.68% Pretax Margin-142.57% Return on Equity-28.80% Return on Assets-25.87% Debt Debt-to-Equity RatioN/A Current Ratio11.12 Quick Ratio11.12 Sales & Book Value Annual Sales$97.07 million Price / Sales11.12 Cash FlowN/A Price / Cash FlowN/A Book Value$19.76 per share Price / Book2.64Miscellaneous Outstanding Shares20,710,000Free Float18,140,000Market Cap$1.08 billion OptionableOptionable Beta0.53 Enanta Pharmaceuticals Frequently Asked Questions Should I buy or sell Enanta Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Enanta Pharmaceuticals stock. View analyst ratings for Enanta Pharmaceuticals or view top-rated stocks. What is Enanta Pharmaceuticals' stock price forecast for 2022? 7 brokerages have issued 1-year price targets for Enanta Pharmaceuticals' shares. Their ENTA stock forecasts range from $44.00 to $103.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $73.43 in the next twelve months. This suggests a possible upside of 41.0% from the stock's current price. View analysts' price targets for Enanta Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Enanta Pharmaceuticals' stock performed in 2022? Enanta Pharmaceuticals' stock was trading at $74.78 on January 1st, 2022. Since then, ENTA shares have decreased by 30.3% and is now trading at $52.09. View the best growth stocks for 2022 here. When is Enanta Pharmaceuticals' next earnings date? Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Enanta Pharmaceuticals. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its quarterly earnings results on Monday, May, 9th. The biotechnology company reported ($1.63) earnings per share for the quarter, missing analysts' consensus estimates of ($1.43) by $0.20. The biotechnology company earned $18.72 million during the quarter, compared to analysts' expectations of $20.40 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 28.80% and a negative net margin of 122.68%. During the same quarter in the prior year, the company earned ($1.09) EPS. View Enanta Pharmaceuticals' earnings history. Who are Enanta Pharmaceuticals' key executives? Enanta Pharmaceuticals' management team includes the following people: Dr. Jay R. Luly, Pres, CEO & Director (Age 66, Pay $1.23M)Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 67, Pay $652.39k)Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 70, Pay $729.75k)Ms. Tara Lynn Kieffer Ph.D., Sr. VP of New Product Strategy & Devel. (Age 44, Pay $496.85k)Mr. Brendan Luu, Sr. VP of Bus. Devel.Ms. Jennifer Viera, Sr. Director of Investor Relations & Corp. CommunicationsMr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 68)Dr. Nathalie Adda M.D., Consultant (Age 56) (LinkedIn Profile) What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO? 3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Enanta Pharmaceuticals' key competitors? Some companies that are related to Enanta Pharmaceuticals include Cerevel Therapeutics (CERE), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Mirati Therapeutics (MRTX), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Cytokinetics (CYTK), Galapagos (GLPG), Bausch Health Companies (BHC), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Harmony Biosciences (HRMY), PTC Therapeutics (PTCT) and Amicus Therapeutics (FOLD). View all of ENTA's competitors. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS). What is Enanta Pharmaceuticals' stock symbol? Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA." How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enanta Pharmaceuticals' stock price today? One share of ENTA stock can currently be purchased for approximately $52.09. How much money does Enanta Pharmaceuticals make? Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $1.08 billion and generates $97.07 million in revenue each year. The biotechnology company earns $-79,000,000.00 in net income (profit) each year or ($5.52) on an earnings per share basis. How many employees does Enanta Pharmaceuticals have? Enanta Pharmaceuticals employs 155 workers across the globe. How can I contact Enanta Pharmaceuticals? Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for Enanta Pharmaceuticals is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530. This page (NASDAQ:ENTA) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here